DM2 X METFORMIN X PREVENTS CV ADVERSE EVENTS

• Patients with diabetes and chronic kidney disease (CKD) were followed to compare outcomes in metformin users and non-users. Metformin users had lower overall mortality rates, cardiovascular mortality rates, and rates of cardiovascular events compared with non-users. The rate of end-stage renal disease (ESRD) was 4.0% among metformin users versus 3.6% in non-users, but there was no significant association between metformin use and the risk of ESRD. Metformin use showed independent associations with a reduced risk of all-cause mortality, cardiovascular death, cardiovascular events, and the kidney disease composite of ESRD and death.
• In patients with stage 3 kidney disease, metformin use may be safe and may reduce the risk of mortality and cardiovascular events